// App-Quantinova.ai

5064 : Phase I trial of docetaxel/prednisone plus fractionated dose radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody 177lu-J591 in patients with metastatic, castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Scott T. Tagawa

Principal Investigators

  • Young E. Whang

  • Gurveen Kaur

  • Himisha Beltran

  • Neil Harrison Bander

  • Anastasia Nikolopoulou

  • Yuliya Jhanwar

  • Arif Sheikh

  • Adam Ireland

  • Carmen Garcias-Espana

  • Stanley J. Goldsmith

Medical Centers

  • Weill Cornell Medical College, New York, NY

  • University of North Carolina, Chapel Hill, NC

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • Metastatic castration-resistant prostate cancer

  • Neutropenia

  • Solid malignancies

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

  • Folate Hydrolase 1

Drug/Treatment

  • MLN591RL

  • Prednisone

  • Docetaxel

  • J591

Outcome

  • Indeterminate

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved